MOTS-c is not FDA-approved, and this HHS document addresses limited enforcement discretion for specified qualifying compounders. In an HHS policy document whose publication/effective status is unconfirmed, HHS states that it does not intend to take enforcement action against specified compounders using MOTS-c acetate when every policy condition is met, including a valid patient-specific prescription and subcutaneous or intramuscular injectable dosage forms. The policy applies to qualifying compounding by specified entities and requires, among other conditions, qualifying sourcing and a patient-specific prescription.
What does the HHS policy actually allow for MOTS-c?
HHS policy places MOTS-c among six peptide bulk substances covered by a limited enforcement-discretion policy while the 503A bulk-substance list is developed through rulemaking. The other five are BPC-157, Epitalon, KPV, Semax, and TB-500.
That is not a blanket permission to buy or use MOTS-c however you choose. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a covered peptide only when all of the policy’s conditions are met. State pharmacy and licensing rules can still matter. The difference between a policy and a final rule is explained in this statute regulation rule or guidance source map.
| Question | What the policy requires |
|---|---|
| Prescription | A valid patient-specific prescription. |
| Permitted MOTS-c route | Subcutaneous or intramuscular injection only. |
| Ingredient | MOTS-c acetate with the identity described in Appendix B. |
| Product format | One Appendix A peptide as the single active pharmaceutical ingredient. |
| Source material | Material from an FDA-registered, CGMP-compliant original manufacturer with a valid certificate of analysis, or through an FDA-registered repacker, relabeler, or reseller meeting the policy’s vendor- and COA-validation conditions. |
| Label | “This is a compounded drug product. Not for resale.” |
| Device | Only an FDA 510(k)-cleared syringe may be co-packaged or contain the compounded drug. |
The pharmacy also must report serious adverse events and product-quality issues to FDA MedWatch and the relevant states. The policy says compounded drugs are not FDA-approved, and it may be revisited if a safety signal or quality issue arises.
Is MOTS-c prescription only?
For the HHS policy pathway, yes: a valid patient-specific prescription is required. The underlying compounding statute likewise ties 503A compounding to patient-specific prescriptions and sets conditions for bulk substances, including registration and certificates of analysis. You can read the statutory framework at 21 U.S.C. 353a.
A prescription alone is not the whole answer. The MOTS-c product, pharmacy or physician, sourcing, labeling, reporting, single-peptide formulation, and injection route must also fit the HHS policy.
Can you buy a MOTS-c peptide online?
A direct-to-consumer research-use-only vial is not within the HHS policy. HHS says the policy is intended to discourage the use of research-use-only peptides supplied by foreign manufacturers. It also does not cover combination vials containing two or more peptides, GHK-Cu, or peptides not named in Appendix A.
If you are considering the policy route, start with a prescriber and a state-licensed 503A pharmacy. Ask the pharmacy whether the prescription will be patient-specific, whether the product is a single-API MOTS-c acetate product, and whether its sourcing and certificate of analysis meet the policy conditions. Do not treat a “research use only” label as the same thing.
What does the research cited for MOTS-c mean?
HHS cites a randomized, placebo-controlled trial of a MOTS-c analogue that reported no serious adverse events at exposure above the compounded regimen. It also cites rodent studies reporting metabolic benefit without systemic toxicity. Those findings concern an analogue trial and rodent studies; they do not create a personal dosing plan or establish what will happen for an individual using compounded MOTS-c.
The FDA’s compounding risk information identifies potential immunogenicity and peptide-impurity or API-characterization concerns for MOTS-C, and says FDA lacks important information about possible harm in people by the proposed routes. That is why the HHS pathway has specific sourcing, testing, pharmacy, and reporting conditions.
Can you take MOTS-c without exercise, forever, or on a set schedule?
The HHS policy does not set a personal dose, course length, maintenance schedule, or exercise requirement for MOTS-c. It sets the federal enforcement-discretion conditions for qualifying compounding, including route and product controls. A prescriber is the appropriate person to discuss whether a proposed prescription is suitable in light of your health history and medicines.
Do not use online “protocols,” kits, or stacking plans as a substitute for that discussion. A combination product with MOTS-c plus another peptide falls outside this policy because the policy requires a single active pharmaceutical ingredient.
Is another peptide comparable to MOTS-c?
HHS covers six named peptides, but they do not share the same permitted routes or product limits. For example, Semax is limited to intranasal use, KPV to topical and oral forms, and BPC-157 has subcutaneous, intramuscular, oral, and topical limits. A different peptide is not automatically a substitute for MOTS-c, and adding one to a MOTS-c product would put the combination outside this policy.
What are your practical options now?
| Option | What it means |
|---|---|
| Discuss a qualifying compounded prescription | When every listed condition is met, HHS says it does not intend to take enforcement action against a qualifying state-licensed pharmacy compounding under this policy. |
| Use an FDA-approved peptide drug | FDA-approved peptide medicines exist for their own labeled uses; they are not interchangeable with MOTS-c. |
| Wait for the final 503A rule | The interim policy applies while rulemaking addresses whether each peptide is included on the 503A bulks list. |
OIRA completed review of the interim peptide-compounding policy on October 27, 2026, with a conclusion of “Consistent with Change.” A Federal Register publication on October 30 has been reported, but that publication is not confirmed by the HHS document.
Before you move forward
- Confirm that the prescription is patient-specific.
- Confirm that the product is MOTS-c acetate alone, not a multi-peptide vial.
- Confirm that the only intended route is subcutaneous or intramuscular injection.
- Ask the pharmacy how it meets the policy’s manufacturer, certificate-of-analysis, labeling, and reporting requirements.
- Ask whether state pharmacy rules affect dispensing to you.
If an agency or court notice creates a separate response date, use a legal deadline organizer to keep the date and proof of service together.
By LegalHelpOnline.org Legal Research & Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.